Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
IF: 2.9 5-Year IF: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN Print: 0743-4863
ISSN Online: 2162-660X

Volumes:
Volume 37, 2020 Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v12.i1.10
pages 1-99

Biodegradable Microspheres in Drug Delivery

Hiroaki Okada
Pharmaceutical Development Laboratories, Production Division, Takeda Chemical Industries, Ltd., 2-17-85 Jusohonmachi, Yodogawa-ku, Osaka 532, Japan
Hajime Toguchi
Research on Research, Takeda Chemical Industries, Ltd., 2-17-85 Jusohonmachi, Yodogawa-ku, Osaka 532, Japan

ABSTRACT

General aspects of biodegradable microspheres prepared from natural and synthesized polymers used in drug delivery systems are reviewed first from various viewpoints: characteristics of biodegradable polymers (physicochemical properties, bioerosion mechanism, biocompatibility), preparation method for the microspheres, drug release from parenteral products and briefly nonparenteral products. The relationship between release pattern and pharmacological activity of therapeutic peptides and proteins and rational controlled release design are also discussed. In the latter half, successful sustained release depot formulations of peptides, leuprorelin acetate, and thyrotropin-releasing hormone (TRH), utilizing poly(lactic acid) (PLA) and poly(lactic/glycolic acid) (PLGA) microspheres are reviewed with respect to preparation, drug release, biocompatibility, pharmacological effects, and results of clinical studies. Thereafter, studies on antitumor therapy by chemoembolization using PLGA microspheres containing an angiogenesis inhibitor (TNP-470) are described as an example of targeted drug delivery with biodegradable microspheres.


Articles with similar content:

Polymeric Nanoparticles for Oral Delivery of Drugs and Vaccines: A Critical Evaluation of In Vivo Studies
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.22, 2005, issue 5
Eric Doelker, Eric Allemann, Sergio A. Galindo-Rodriguez, Hatem Fessi
Polymeric Mixed Micelles: Improving the Anticancer Efficacy of Single-Copolymer Micelles
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.36, 2019, issue 1
Arehalli S. Manjappa, Ajit B. Patil, Popat S. Kumbhar, Vandana B. Patravale, John I. Disouza
Mucosal Drug Delivery: Membranes, Methodologies, and Applications
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.21, 2004, issue 3
Bozena Michniak, Yifan Song, Rashmi Thakur, Victor M. Meidan, Yiping Wang
Lipid-Based Cochleates: A Promising Formulation Platform for Oral and Parenteral Delivery of Therapeutic Agents
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.24, 2007, issue 1
Emilio Squillante, III, Kwon H. Kim, Ravi Rao
The Role of Surface Functionalization in the Design of PLGA Micro- and Nanoparticles
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.27, 2010, issue 1
Michael Wirth, Vera Kerleta, Christian Fillafer, Franz Gabor, Gerda Ratzinger